Drugs /

filgrastim

Back to Drugs List

Overview

NCI Definition [1]:
A recombinant, non-glycosylated cytokine which is chemically identical to or similar to the endogenous cytokine human granulocyte colony-stimulating factor (G-CSF) isoform B, with immunomodulating activity. Filgrastim binds to and activates G-CSF receptors with the same biological activity and stability as the endogenous cytokine, thereby controlling the production, differentiation, and function of neutrophilic granulocyte progenitors.

Clinical Trials

View Clinical Trials for filgrastim

Filgrastim has been investigated in 46 clinical trials, of which 35 are open and 11 are closed. Of the trials investigating filgrastim, 2 are early phase 1 (1 open), 10 are phase 1 (6 open), 12 are phase 1/phase 2 (8 open), 18 are phase 2 (16 open), 3 are phase 3 (3 open), and 1 is phase 4 (1 open).

del(5)(q10), KMT2A Fusion, and Monosomy 7 are the most frequent biomarker inclusion criteria for filgrastim clinical trials.

Acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndromes are the most common diseases being investigated in filgrastim clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Filgrastim
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Filgrastim
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating filgrastim and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
neupogen, filgrastim-sndz, filgrastim, g-csf, r-methug-csf, rg-csf, tbo-filgrastim, filgrastim (product), g-csf - recombinant human granulocyte-colony stimulating factor, grasin, filgrastrim, filgrastim [chemical/ingredient], g-csf recombinant, human methionyl, nivestim, g csf, filgrastim xm02, tbo-filgrastim, granulocyte colony-stimulating factor, tevagrastim, g csf recombinant, human methionyl, filgrastim, filgrastim-sndz, recombinant methionyl human granulocyte colony stimulating factor, zarxio, filgrastim (substance), granix, 121181-53-1, tbo-filgrastim, filgrastim xm02, granulocyte colony stimulating factor, r methug csf, filgrastim-sndz, r-methug-csf, recombinant-methionyl human granulocyte colony-stimulating factor
NCIT ID [1]:
C1474
SNOMED ID [1]:
F-61B55

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.